Peptides DB
Research-centric peptide and protocol reference hub

CJC-1295 vs KPV

Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team

CJC-1295: Research use — not FDA-approvedKPV: Research use — not FDA-approved

A data-driven comparison of CJC-1295 and KPV (also searched as KPV vs CJC-1295) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

CJC-1295 centers on muscle, while KPV leans toward healing. On indexed research, KPV is ahead (CJC-1295: 12 studies, Human clinical; KPV: 21, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • •CJC-1295 is strongest for muscle; KPV for healing.
  • •Evidence: CJC-1295 Human clinical (12 studies) vs KPV Human evidence (21).
  • •Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

CJC-1295KPV

At a glance

CJC-1295Human clinical

GHRH analogue | GH/IGF-1 modulation

Strongest: MuscleStudies: 12Level: Moderate Research
KPVHuman evidence

Immunomodulation | Wound healing

Strongest: HealingStudies: 21Level: Preclinical

CJC-1295 vs KPV: side-by-side

MetricCJC-1295KPV
ClassMuscleHealing
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman clinicalHuman evidence
Studies indexed1221
Research levelModerate ResearchPreclinical
Strongest effectMuscle & body compHealing & recovery
Healing & recovery2.04.0▲
Muscle & body comp4.0▲1.0
Metabolic & appetite3.0▲1.0
Neuro & mood2.0▲1.0
Sleep & circadian3.0▲0.0
Inflammation & immune1.04.0▲
Skin & aesthetics2.0▲2.0▲

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyCJC-1295KPV
MechanismGHRH (1–29) analog, modifiedModulation of inflammatory responses
RouteSubcutaneous injection—
Half-life~30 min—

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is CJC-1295?

GHRH analogue used in research contexts for GH/IGF-1 modulation, muscle and bone density, sleep, and recovery.

Full CJC-1295 profile, mechanism & studies →

What is KPV?

KPV is a tripeptide composed of lysine, proline, and valine, which has been studied for its potential immunomodulatory and wound healing properties. Its mechanism of action is thought to involve the modulation of inflammatory responses, potentially through the inhibition of pro-inflammatory cytokines and promotion of anti-inflammatory pathways. KPV may also enhance the healing process by promoting angiogenesis and fibroblast proliferation, which are critical for tissue repair.

Full KPV profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingKPV4.0/5 effect signal
MuscleCJC-12954.0/5 effect signal
MetabolicCJC-12953.0/5 effect signal
NeuroCJC-12952.0/5 effect signal
SleepCJC-12953.0/5 effect signal
InflammationKPV4.0/5 effect signal
SkinEvenBoth ~2.0/5

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack CJC-1295 and KPV?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

CJC-1295 vs KPV: side effects

CJC-1295

No community-reported effects logged yet.

KPV

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

CJC-1295 has 12 approved studies indexed (Human clinical), and KPV has 21 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is CJC-1295 or KPV better?

It depends on your goal. CJC-1295 is strongest for muscle; KPV for healing. KPV has more indexed studies (21). See the goal-by-goal breakdown above.

Is CJC-1295 or KPV better for weight loss?

CJC-1295 shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.

Is CJC-1295 or KPV better for muscle?

CJC-1295 leads on the muscle & body-composition axis (4.0/5).

Which has more research, CJC-1295 or KPV?

CJC-1295 has 12 approved studies indexed (Human clinical); KPV has 21 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack CJC-1295 and KPV?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of CJC-1295 vs KPV?

CJC-1295: no community-reported effects logged yet. KPV: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is CJC-1295 or KPV FDA-approved?

CJC-1295 is a research-use compound and is not FDA-approved. KPV is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is KPV better than CJC-1295?

For healing, KPV has the edge; for muscle, CJC-1295 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

CJC-1295 and KPV are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.